BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trevisiol C, Gion M, Vaona A, Fabricio ASC, Roca E, Licitra L, Alfieri S, Bossi P. The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. Oral Oncol 2021;114:105128. [PMID: 33444925 DOI: 10.1016/j.oraloncology.2020.105128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Aulakh SS, Silverman DA, Young K, Dennis SK, Birkeland AC. The Promise of Circulating Tumor DNA in Head and Neck Cancer. Cancers (Basel) 2022;14:2968. [PMID: 35740633 DOI: 10.3390/cancers14122968] [Reference Citation Analysis]
2 De Felice F, Vai A, Camarda AM, Iacovelli NA, Orlandi E. Lower-Neck Sparing Using Proton Therapy in Patients with Uninvolved Neck Nasopharyngeal Carcinoma: Is It Safe? J Clin Med 2022;11:3297. [PMID: 35743368 DOI: 10.3390/jcm11123297] [Reference Citation Analysis]
3 Li Q, Yu L, Yang P, Hu Q. Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era. Cancer Manag Res 2021;13:6799-810. [PMID: 34512020 DOI: 10.2147/CMAR.S311094] [Reference Citation Analysis]
4 Lee AWM, Lee VHF, Ng WT, Strojan P, Saba NF, Rinaldo A, Willems SM, Rodrigo JP, Forastiere AA, Ferlito A. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer 2021;153:109-22. [PMID: 34153713 DOI: 10.1016/j.ejca.2021.05.022] [Cited by in F6Publishing: 8] [Reference Citation Analysis]